Medicure Inc. (OTCMKTS:MCUJF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

According to Zacks, “Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. “

Separately, ValuEngine upgraded shares of Medicure from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th.

Medicure (MCUJF) opened at 6.15 on Friday. The firm’s 50-day moving average is $6.39 and its 200 day moving average is $6.26. Medicure has a 12 month low of $4.11 and a 12 month high of $7.96. The firm has a market capitalization of $96.14 million, a price-to-earnings ratio of 5.71 and a beta of 0.59.

ILLEGAL ACTIVITY WARNING: “Medicure Inc. (MCUJF) Downgraded by Zacks Investment Research to “Hold”” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at

Medicure Company Profile

Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).

Receive News & Ratings for Medicure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.